• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jepicomhInstructions for authorsCurrent TOCJournal of Epidemiology and Community Health
J Epidemiol Community Health. Sep 2005; 59(9): 740–748.
PMCID: PMC1733142

Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives

Abstract

Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women's health initiative, indicated that long term use of oestrogen plus progestin HRT not only was associated with increased risk of cancer but, contrary to expectations, did not decrease, and may have increased, risk of cardiovascular disease. In June 2004 a group of historians, epidemiologists, biologists, clinicians, and women's health advocates met to discuss the scientific and social context of and response to these findings. It was found that understanding the evolving and contending knowledge on hormones and health requires: (1) considering its societal context, including the impact of the pharmaceutical industry, the biomedical emphasis on individualised risk and preventive medicine, and the gendering of hormones; and (2) asking why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already demonstrated, three decades earlier, to be carcinogenic? Answering this question requires engaging with core issues of accountability, complexity, fear of mortality, and the conduct of socially responsible science.

Full Text

The Full Text of this article is available as a PDF (111K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605–613. [PubMed]
  • Petitti Diana B. Hormone replacement therapy for prevention: more evidence, more pessimism. JAMA. 2002 Jul 3;288(1):99–101. [PubMed]
  • WILSON RA, WILSON TA. The fate of the nontreated postmenopausal woman: a plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc. 1963 Apr;11:347–362. [PubMed]
  • Rhoades FP. Minimizing the menopause. J Am Geriatr Soc. 1967 Apr;15(4):346–354. [PubMed]
  • Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991 Jan;20(1):47–63. [PubMed]
  • Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999 Jun 10;340(23):1801–1811. [PubMed]
  • Barrett-Connor E, Stuenkel CA. Hormone replacement therapy (HRT)--risks and benefits. Int J Epidemiol. 2001 Jun;30(3):423–426. [PubMed]
  • Ettinger Bruce, Grady Deborah, Tosteson Anna N A, Pressman Alice, Macer Judith L. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol. 2003 Dec;102(6):1225–1232. [PubMed]
  • Hersh Adam L, Stefanick Marcia L, Stafford Randall S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004 Jan 7;291(1):47–53. [PubMed]
  • Buist Diana S M, Newton Katherine M, Miglioretti Diana L, Beverly Kevin, Connelly Maureen T, Andrade Susan, Hartsfield Cynthia L, Wei Feifei, Chan K Arnold, Kessler Larry. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004 Nov;104(5 Pt 1):1042–1050. [PubMed]
  • Majumdar Sumit R, Almasi Elizabeth A, Stafford Randall S. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004 Oct 27;292(16):1983–1988. [PubMed]
  • Grodstein Francine, Clarkson Thomas B, Manson JoAnn E. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003 Feb 13;348(7):645–650. [PubMed]
  • Stampfer Meir. Commentary: hormones and heart disease: do trials and observational studies address different questions? Int J Epidemiol. 2004 Jun;33(3):454–455. [PubMed]
  • Vandenbroucke Jan P. Commentary: the HRT story: vindication of old epidemiological theory. Int J Epidemiol. 2004 Jun;33(3):456–457. [PubMed]
  • Barrett-Connor Elizabeth. Commentary: observation versus intervention--what's different? Int J Epidemiol. 2004 Jun;33(3):457–459. [PubMed]
  • Kuller Lewis H. Commentary: hazards of studying women: the oestrogen oestrogen/progesterone dilemma. Int J Epidemiol. 2004 Jun;33(3):459–460. [PubMed]
  • Petitti Diana. Commentary: hormone replacement therapy and coronary heart disease: four lessons. Int J Epidemiol. 2004 Jun;33(3):461–463. [PubMed]
  • Lawlor Debbie A, Davey Smith George, Ebrahim Shah. Commentary: the hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol. 2004 Jun;33(3):464–467. [PubMed]
  • Krieger Nancy. Postmenopausal hormone therapy. N Engl J Med. 2003 Jun 5;348(23):2363–2364. [PubMed]
  • Oxford AE. Observations Concerning the Growth and Metabolic Activities of Myxococci in a Simple Protein-free Liquid Medium. J Bacteriol. 1947 Feb;53(2):129–138. [PMC free article] [PubMed]
  • Weinstein MC. Estrogen use in postmenopausal women--costs, risks, and benefits. N Engl J Med. 1980 Aug 7;303(6):308–316. [PubMed]
  • Hoover R, Gray LA, Sr, Cole P, MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med. 1976 Aug 19;295(8):401–405. [PubMed]
  • Ross RK, Paganini-Hill A, Gerkins VR, Mack TM, Pfeffer R, Arthur M, Henderson BE. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980 Apr 25;243(16):1635–1639. [PubMed]
  • Notelovitz M. Estrogen replacement therapy: indications, contraindications, and agent selection. Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1832–1841. [PubMed]
  • Bell SE. Changing ideas: the medicalization of menopause. Soc Sci Med. 1987;24(6):535–542. [PubMed]
  • Rosenberg L. Hormone replacement therapy: the need for reconsideration. Am J Public Health. 1993 Dec;83(12):1670–1673. [PMC free article] [PubMed]
  • Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994 May 14;308(6939):1268–1269. [PMC free article] [PubMed]
  • Haenszel W, Curnen MG. The first fifty years of the Connecticut Tumor Registry: reminiscences and prospects. Yale J Biol Med. 1986 Sep-Oct;59(5):475–484. [PMC free article] [PubMed]
  • Löwy Ilana, Weisz George. French hormones: progestins and therapeutic variation in France. Soc Sci Med. 2005 Jun;60(11):2609–2622. [PubMed]
  • Mann C. Women's health research blossoms. Science. 1995 Aug 11;269(5225):766–770. [PubMed]
  • Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol. 1985 Mar;65(3):441–446. [PubMed]
  • Palmlund I. The marketing of estrogens for menopausal and postmenopausal women. J Psychosom Obstet Gynaecol. 1997 Jun;18(2):158–164. [PubMed]
  • Palmlund I. The social construction of menopause as risk. J Psychosom Obstet Gynaecol. 1997 Jun;18(2):87–94. [PubMed]
  • Houck Judith A. "What do these women want?": Feminist responses to Feminine Forever, 1963-1980. Bull Hist Med. 2003 Spring;77(1):103–132. [PubMed]
  • Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996;17:47–67. [PubMed]
  • Lawlor Debbie A, Ebrahim Shah, Davey Smith George. Role of endogenous oestrogen in aetiology of coronary heart disease: analysis of age related trends in coronary heart disease and breast cancer in England and Wales and Japan. BMJ. 2002 Aug 10;325(7359):311–312. [PMC free article] [PubMed]
  • Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998 May 9;351(9113):1425–1427. [PubMed]
  • La Croix AZ, Newton KM, Leveille SG, Wallace J. Healthy aging. A women's issue. West J Med. 1997 Oct;167(4):220–232. [PMC free article] [PubMed]
  • Khaw KT. Healthy aging. BMJ. 1997 Oct 25;315(7115):1090–1096. [PMC free article] [PubMed]
  • Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975 Dec 4;293(23):1164–1167. [PubMed]
  • Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4;293(23):1167–1170. [PubMed]
  • Postmenopausal estrogen use and heart disease. N Engl J Med. 1986 Jul 10;315(2):131–136. [PubMed]
  • McPherson Klim, Hemminki Elina. Synthesising licensing data to assess drug safety. BMJ. 2004 Feb 28;328(7438):518–520. [PMC free article] [PubMed]
  • Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992 Dec 15;117(12):1016–1037. [PubMed]
  • Lawlor Debbie A, Smith George Davey, Ebrahim Shah. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials. Am J Public Health. 2004 Dec;94(12):2149–2154. [PMC free article] [PubMed]
  • Krieger N. Theories for social epidemiology in the 21st century: an ecosocial perspective. Int J Epidemiol. 2001 Aug;30(4):668–677. [PubMed]
  • Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991 Sep 15;115(6):455–456. [PubMed]
  • Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol. 1993 Dec;82(6):1021–1028. [PubMed]
  • Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology. 1995 May;6(3):227–231. [PubMed]
  • Petitti DB. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol. 1994 Mar;4(2):115–118. [PubMed]
  • Vandenbroucke JP. Postmenopausal oestrogen and cardioprotection. Lancet. 1991 Jun 15;337(8755):1482–1483. [PubMed]
  • Barkhem Tomas, Nilsson Stefan, Gustafsson Jan-Ake. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics. 2004;4(1):19–28. [PubMed]
  • McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev. 2001 Jun;22(3):319–341. [PubMed]
  • Soto AM, Sonnenschein C. The two faces of janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst. 2001 Nov 21;93(22):1673–1675. [PubMed]
  • Markey Caroline M, Rubin Beverly S, Soto Ana M, Sonnenschein Carlos. Endocrine disruptors: from Wingspread to environmental developmental biology. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):235–244. [PubMed]
  • Thornton Joseph W, McCally Michael, Houlihan Jane. Biomonitoring of industrial pollutants: health and policy implications of the chemical body burden. Public Health Rep. 2002 Jul-Aug;117(4):315–323. [PMC free article] [PubMed]
  • Egeland GM, Sweeney MH, Fingerhut MA, Wille KK, Schnorr TM, Halperin WE. Total serum testosterone and gonadotropins in workers exposed to dioxin. Am J Epidemiol. 1994 Feb 1;139(3):272–281. [PubMed]
  • Yu ML, Guo YL, Hsu CC, Rogan WJ. Menstruation and reproduction in women with polychlorinated biphenyl (PCB) poisoning: long-term follow-up interviews of the women from the Taiwan Yucheng cohort. Int J Epidemiol. 2000 Aug;29(4):672–677. [PubMed]
  • Koopman-Esseboom C, Morse DC, Weisglas-Kuperus N, Lutkeschipholt IJ, Van der Paauw CG, Tuinstra LG, Brouwer A, Sauer PJ. Effects of dioxins and polychlorinated biphenyls on thyroid hormone status of pregnant women and their infants. Pediatr Res. 1994 Oct;36(4):468–473. [PubMed]
  • Patandin S, Lanting CI, Mulder PG, Boersma ER, Sauer PJ, Weisglas-Kuperus N. Effects of environmental exposure to polychlorinated biphenyls and dioxins on cognitive abilities in Dutch children at 42 months of age. J Pediatr. 1999 Jan;134(1):33–41. [PubMed]
  • Ulrich EM, Caperell-Grant A, Jung SH, Hites RA, Bigsby RM. Environmentally relevant xenoestrogen tissue concentrations correlated to biological responses in mice. Environ Health Perspect. 2000 Oct;108(10):973–977. [PMC free article] [PubMed]
  • DeVito MJ, Birnbaum LS, Farland WH, Gasiewicz TA. Comparisons of estimated human body burdens of dioxinlike chemicals and TCDD body burdens in experimentally exposed animals. Environ Health Perspect. 1995 Sep;103(9):820–831. [PMC free article] [PubMed]
  • Gray LE, Ostby JS, Kelce WR. A dose-response analysis of the reproductive effects of a single gestational dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin in male Long Evans Hooded rat offspring. Toxicol Appl Pharmacol. 1997 Sep;146(1):11–20. [PubMed]
  • Haag Eric S. Meeting review: the microevolution of development. Evol Dev. 2003 Jan-Feb;5(1):1–2. [PubMed]
  • Ekbom A, Trichopoulos D, Adami HO, Hsieh CC, Lan SJ. Evidence of prenatal influences on breast cancer risk. Lancet. 1992 Oct 24;340(8826):1015–1018. [PubMed]
  • Henderson IC. Risk factors for breast cancer development. Cancer. 1993 Mar 15;71(6 Suppl):2127–2140. [PubMed]
  • Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr. 2000;(27):17–37. [PubMed]
  • Hunt Patricia A, Koehler Kara E, Susiarjo Martha, Hodges Craig A, Ilagan Arlene, Voigt Robert C, Thomas Sally, Thomas Brian F, Hassold Terry J. Bisphenol a exposure causes meiotic aneuploidy in the female mouse. Curr Biol. 2003 Apr 1;13(7):546–553. [PubMed]
  • Kurebayashi Hideo, Betsui Hiroshi, Ohno Yasuo. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide. Toxicol Sci. 2003 May;73(1):17–25. [PubMed]
  • Oberg Mattias, Sjödin Andreas, Casabona Helena, Nordgren Ingrid, Klasson-Wehler Eva, Håkansson Helen. Tissue distribution and half-lives of individual polychlorinated biphenyls and serum levels of 4-hydroxy-2,3,3',4',5-pentachlorobiphenyl in the rat. Toxicol Sci. 2002 Dec;70(2):171–182. [PubMed]
  • Krieger N, Northridge M, Gruskin S, Quinn M, Kriebel D, Davey Smith G, Bassett M, Rehkopf DH, Miller C. Assessing health impact assessment: multidisciplinary and international perspectives. J Epidemiol Community Health. 2003 Sep;57(9):659–662. [PMC free article] [PubMed]
  • Kriebel D, Tickner J. Reenergizing public health through precaution. Am J Public Health. 2001 Sep;91(9):1351–1355. [PMC free article] [PubMed]
  • Larson Eric B, Fihn Stephan D, Kirk Lynne M, Levinson Wendy, Loge Ronald V, Reynolds Eileen, Sandy Lewis, Schroeder Steven, Wenger Neil, Williams Mark, et al. The future of general internal medicine. Report and recommendations from the Society of General Internal Medicine (SGIM) Task Force on the Domain of General Internal Medicine. J Gen Intern Med. 2004 Jan;19(1):69–77. [PMC free article] [PubMed]
  • Ma Jun, Stafford Randall S, Cockburn Iain M, Finkelstein Stan N. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther. 2003 May;25(5):1503–1517. [PubMed]
  • Sackett David L. The arrogance of preventive medicine. CMAJ. 2002 Aug 20;167(4):363–364. [PMC free article] [PubMed]
  • Notelovitz M. Estrogen replacement therapy: indications, contraindications, and agent selection. Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1832–1841. [PubMed]
  • Nawaz H, Katz DL. American College of Preventive Medicine Practice Policy Statement: perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med. 1999 Oct;17(3):250–254. [PubMed]
  • Watkins Elizabeth Siegel. "Doctor, are you trying to kill me?": ambivalence about the patient package insert for estrogen. Bull Hist Med. 2002 Spring;76(1):84–104. [PubMed]
  • Fee E, Krieger N. Understanding AIDS: historical interpretations and the limits of biomedical individualism. Am J Public Health. 1993 Oct;83(10):1477–1486. [PMC free article] [PubMed]
  • Kopera H. The dawn of hormone replacement therapy. Maturitas. 1991 Sep;13(3):187–188. [PubMed]
  • Ettinger B. Overview of estrogen replacement therapy: a historical perspective. Proc Soc Exp Biol Med. 1998 Jan;217(1):2–5. [PubMed]
  • Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol. 1985 Mar;65(3):441–446. [PubMed]
  • Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995 Jan;85(1):6–10. [PubMed]
  • Kaufert PA, Lock M. Medicalization of women's third age. J Psychosom Obstet Gynaecol. 1997 Jun;18(2):81–86. [PubMed]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...